Table 2.

Risperidone compared to TBZ

Results of Propensity Score Matched Analysis
	Direction of favorable Δ	TBZ Group	Risperidone Group	P‐value
N		72	72
Primary Outcome Measure
Annual rate of Δ of TMS	−	5.70 ± 10.92	1.47 ± 10.49	0.019
Secondary Outcome Measures
Absolute Δ of TMS	−	6.29 ± 11.95	1.29 ± 10.57	0.009
Percent Δ of TMS	−	20.86 ± 40.86	8.26 ± 33.94	0.046
Annualized percent Δ of TMS	−	19.05 ± 38.25	8.97 ± 35.34	0.103
Annual rate of Δ of total chorea score	−	−0.02 ± 5.09	−0.20 ± 4.73	0.826
Annual rate of Δ of TFC	+	−0.70 ± 1.89	−0.47 ± 1.80	0.454
Annual rate of Δ of weight (kg)	+	−1.08 ± 7.03	−1.12 ± 6.55	0.972
Annual rate of Δ of BMI (kg/m2)	+	−0.34 ± 2.38	−0.34 ± 2.40	0.998
Exploratory Outcome Measures
% with annual rate of Δ of TMS ≤ −3.3	+	16.7%	33.3%	.023

Results of Sub‐Analysis
	Direction of favorable Δ	TBZ Group	Risperidone Group	p‐value
N		18	11
Primary Outcome Measure
Annual rate of Δ of TMS	−	3.58 ± 8.28	0.40 ± 10.56	0.374
Secondary Outcome Measures
Absolute Δ of TMS	−	3.56 ± 9.60	0.36 ± 8.62	0.375
Percent Δ of TMS	−	16.89 ± 30.38	−4.58 ± 26.12	0.063
Annualized percent Δ of TMS	−	17.58 ± 29.96	−5.23 ± 26.89	0.048
Annual rate of Δ of total chorea score	−	−0.76 ± 0.3.98	−0.34 ± 4.07	0.788
Annual rate of Δ of TFC	+	−0.33 ± 1.82	0.37 ± 1.15	0.263
Annual rate of Δ of weight (kg)	+	0.72 ± 4.54	5.45 ± 14.45	0.204
Annual rate of Δ of BMI (kg/m2)	+	0.31 ± 1.63	1.89 ± 4.91	0.215
Exploratory Outcome Measures
% with annual rate of Δ of TMS ≤ −3.3	+	11.1%	45.5%	.049

Abbreviations: BMI, baseline body mass index; TBZ, tetrabenazine; TFC, total functional capacity score; TMS, total motor score.

All results that are not percentages represent mean ± standard deviation.